This technology is a synthetic peptide therapeutic that suppresses IL-6 production for treating acute inflammatory conditions such as sepsis and endotoxin shock.
Current treatment methods for endotoxin shock and sepsis rely heavily on supportive care and antibiotics, but they do not directly modulate the underlying inflammatory response. In severe cases, elevated levels of IL-6 and other cytokines lead to a hyperinflammatory state, or “cytokine storm,” that can rapidly cause organ failure and death. While biologics targeting IL-6 signaling exist, they are often expensive, slow acting, or poorly suited to acute settings. Although these methods save lives, there are no fast therapeutics that can directly suppress IL-6 production at the source and improve outcomes in acute inflammatory diseases
This technology is a synthetic peptide that binds to a regulatory protein that stabilizes IL-6 mRNA, thereby reducing IL-6 production at the transcriptional level. By disrupting the interaction between the regulatory protein and its target transcripts, the peptide downregulates IL-6 expression without interfering with upstream immune signaling pathways. This mechanism allows for selective suppression of IL-6-driven inflammation, potentially reducing the risk of systemic immunosuppression seen with other anti-cytokine therapies.
The technology has been validated in both murine and human macrophage cultures.
Patent Pending
IR CU24063
Licensing Contact: Kristin Neuman
